The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Fadia T. Shaya

Department of Pharmaceutical Health Services Research

University of Maryland School of Pharmacy

Baltimore

MD 21201

USA

[email]@rx.umaryland.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA. 2009 - 2013
  • Center on Drugs and Public Policy, University of Maryland School of Pharmacy, Pharmaceutical Health Services Research, 220 Arch Street, USA. 2002 - 2009
  • Associate Professor and Associate Director, University of Maryland, Center on Drugs & Public Policy, School of Pharmacy, USA. 2007
  • University of Maryland School of Pharmacy, 220 Arch St., 12th Fl., Baltimore, USA. 2007
  • University of Maryland School of Pharmacy, Center on Drugs and Public Policy, 515 West Lombard Street, 2nd Floor, USA. 2004 - 2006
  • Department of Epidemiology and Preventive Medicine, University of Maryland, 515 West Lombard St, Baltimore, USA. 2006

References

  1. Social networks help control hypertension. Shaya, F.T., Chirikov, V.V., Daniel Mullins, C., Shematek, J., Howard, D., Foster, C., Saunders, E. J. Clin. Hypertens. (Greenwich) (2013) [Pubmed]
  2. Predictors of compliance with antihypertensive therapy in a high-risk medicaid population. Shaya, F.T., Du, D., Gbarayor, C.M., Frech-Tamas, F., Lau, H., Weir, M.R. J. Natl. Med. Assoc (2009) [Pubmed]
  3. Burden of COPD, asthma, and concomitant COPD and asthma among adults: racial disparities in a medicaid population. Shaya, F.T., Maneval, M.S., Gbarayor, C.M., Sohn, K., Dalal, A.A., Du, D., Scharf, S.M. Chest (2009) [Pubmed]
  4. Elevated economic burden in obstructive lung disease patients with concomitant sleep apnea syndrome. Shaya, F.T., Lin, P.J., Aljawadi, M.H., Scharf, S.M. Sleep. Breath (2009) [Pubmed]
  5. School-based obesity interventions: a literature review. Shaya, F.T., Flores, D., Gbarayor, C.M., Wang, J. J. Sch. Health (2008) [Pubmed]
  6. Burden of concomitant asthma and COPD in a Medicaid population. Shaya, F.T., Dongyi, D., Akazawa, M.O., Blanchette, C.M., Wang, J., Mapel, D.W., Dalal, A., Scharf, S.M. Chest (2008) [Pubmed]
  7. Health-related quality of life as a potential predictor in chronic obstructive lung disease patients. Shaya, F.T., Samant, N., Pradel, F., Mullins, C.D., Scharf, S.M., Britt, J. Expert. Rev. Pharmacoecon. Outcomes. Res (2007) [Pubmed]
  8. Diabetic retinopathy. Shaya, F.T., Aljawadi, M. Clin. Ophthalmol (2007) [Pubmed]
  9. A perspective on African American participation in clinical trials. Shaya, F.T., Gbarayor, C.M., Huiwen Keri Yang, , Agyeman-Duah, M., Saunders, E. Contemporary. Clinical. Trials (2007) [Pubmed]
  10. Bridging the gap between pharmacoeconomics and the real-world practice of managed care pharmacy. Shaya, F.T., Ohsfeldt, R.L. J. Manag. Care. Pharm (2007) [Pubmed]
  11. Addressing cardiovascular disparities through community interventions. Shaya, F.T., Gu, A., Saunders, E. Ethn. Dis (2006) [Pubmed]
  12. New treatment approaches to diabetes. Shaya, F.T., Deshpande, G. Manag. Care (2006) [Pubmed]
  13. Drug therapy persistence and stroke recurrence. Shaya, F.T., El Khoury, A.C., Mullins, C.D., Du, D., Skolasky, R., Fatodu, H., Garber, H., Weir, M.R. Am. J. Manag. Care (2006) [Pubmed]
  14. The case for cultural competence in health professions education. Shaya, F.T., Gbarayor, C.M. Am. J. Pharm. Educ (2006) [Pubmed]
  15. Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. Shaya, F.T., Blume, S.W., Blanchette, C.M., Weir, M.R., Mullins, C.D. Arch. Intern. Med. (2005) [Pubmed]
  16. Prescriptions for cyclooxygenase-2 inhibitors and other nonsteroidal anti-inflammatory agents in a medicaid managed care population: African Americans versus Caucasians. Shaya, F.T., Blume, S. Pain. Med (2005) [Pubmed]
  17. Medicaid managed care: disparities in the use of thiazolidinediones compared with metformin. Shaya, F.T., Shin, J.Y., Mullins, D., Fatodu, H.O., Gu, A., Saunders, E. J. Natl. Med. Assoc (2005) [Pubmed]
  18. Assessing potential risks and evaluating expected benefits. Shaya, F.T., Gu, A. Manag. Care. Interface (2005) [Pubmed]
  19. Compliance with medicine. Shaya, F.T. Ophthalmol. Clin. North. Am (2005) [Pubmed]
  20. Modeling risk of gastrointestinal events among Medicaid NSAID users using propensity scores. Shaya, F.T., Samant, N., Skolasky, R., Saunders, E. Expert. Rev. Pharmacoecon. Outcomes. Res (2005) [Pubmed]
  21. Developing benchmarks for adherence studies. Shaya, F.T., Khoury, A.C. Expert. Rev. Pharmacoecon. Outcomes. Res (2005) [Pubmed]
  22. Review of cost-effectiveness studies of pegylated therapies for hepatitis C. Shaya, F.T., Klaskala, W., Mullins, C.D. Expert. Rev. Pharmacoecon. Outcomes. Res (2005) [Pubmed]
  23. Prescription drug spending trends for the privately insured in Maryland, 2000-2001. Shaya, F.T., Blume, S., Mullins, C.D. Health. Aff. (Millwood) (2004) [Pubmed]
  24. Formulary decision-making considerations: COX-2 inhibitors. Shaya, F.T., Wong, W., Shin, J.Y., Martin, L., Samant, N. Manag. Care. Interface (2004) [Pubmed]
  25. Clinical and economic evaluation of gatifloxacin and levofloxacin. Shaya, F.T., Shin, J.Y., Wong, W.I., Proveaux, W. Expert. Rev. Pharmacoecon. Outcomes. Res (2004) [Pubmed]
  26. Cost studies in clinical trials. Shaya, F.T., Samant, N. Expert. Rev. Pharmacoecon. Outcomes. Res (2004) [Pubmed]
  27. Formulary decision methodology in the context of health system costs and insurance trends. Shaya, F.T., Samant, N. Expert. Rev. Pharmacoecon. Outcomes. Res (2004) [Pubmed]
  28. Incidence versus prevalence modeling in pharmacoeconomics. Shaya, F.T., Mullins, C.D., Wong, W. Expert. Rev. Pharmacoecon. Outcomes. Res (2002) [Pubmed]
 
WikiGenes - Universities